# Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion

> **NCT04895657** · PHASE4 · COMPLETED · sponsor: **Ain Shams University** · enrollment: 56 (actual)

## Conditions studied

- Gram-Negative Infections

## Interventions

- **DRUG:** Piperacillin/Tazobactam Continuous infusion
- **DRUG:** Piperacillin/Tazobactam Intermittent infusion

## Key facts

- **NCT ID:** NCT04895657
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-27
- **Primary completion:** 2020-01-26
- **Final completion:** 2020-01-26
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04895657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04895657, "Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04895657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*